Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | MPL | P40238 | 2/20 | 0.41 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.39 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP3 | Q9H4L4 | 1/20 | 0.39 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.39 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9748451 | 0.86 | GPR55 (0.42) | SLC2A1CNR2GPR55ALDH1A1CNR1 | |
| SCHEMBL9750351 | 0.86 | CNR2 (0.42) | SLC2A1CNR2GPR55ALDH1A1 | |
| SCHEMBL9748849 | 0.77 | PTPN1 (0.47) | CNR2GPR55CNR1 | |
| SCHEMBL9749291 | 0.75 | CNR2 (0.43) | CNR2GPR55ALDH1A1CNR1 | |
| SCHEMBL9141423 | 0.75 | KMT2A (0.60) | MPLALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL9749576 | 0.75 | CNR2 (0.44) | CNR2GPR55ALDH1A1CNR1 | |
| SCHEMBL9749737 | 0.75 | GPR55 (0.47) | CNR2GPR55ALDH1A1 | |
| SCHEMBL11164122 | 0.74 | TTR (0.43) | — | |
| SCHEMBL48093 | 0.73 | MAPT (0.41) | SLC2A1MPLSUMO2SUMO1SENP7 | |
| SCHEMBL11239311 | 0.72 | TTR (0.49) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0201071-B1 | 2-SUBSTITUTED-1-NAPHTHOLS AS 5-LIPOXYGENASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-03-04 | — | — | EP | disclosed |
| US-5026759-A | Antiinflammatory agents respiratory system disorders | DU PONT MERCK PHARMACEUTICAL (US) | 1991-06-25 | — | — | US | disclosed |
| US-4985442-A | ANTIINFLAMMATORY, LUNG DISEASES, PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4985435-A | TREATMENT OF INFLAMMATION, OBSTRUCTIVE LUNG DISEASES AND PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4906636-A | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-06 | — | — | US | disclosed |
| US-4833164-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-23 | — | — | US | disclosed |
| EP-0201071-A2 | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1986-11-12 | — | — | EP | disclosed |